# Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

> **NCT01307618** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 10 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IV Skin Melanoma

## Interventions

- **BIOLOGICAL:** NA17.A2 Peptide Vaccine
- **BIOLOGICAL:** Recombinant MAGE-3.1 Antigen
- **BIOLOGICAL:** Recombinant Interleukin-12
- **BIOLOGICAL:** MART-1 Antigen
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01307618
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2015-01
- **Final completion:** 2015-02
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Due to lack of clinical efficacy and lack of drug supply, trial was closed early and correlative studies were not pursued further.
- **Last updated:** 2016-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01307618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01307618, "Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01307618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*